Nitin Jain
Experienced in Spontaneous Bacterial Peritonitis

Dr. Nitin Jain

Radiology
Henry Ford St. John Hospital
22101 Moross Rd, 
Detroit, MI 
Clinical Trials:Currently Recruiting for 1 Trial
Experienced in Spontaneous Bacterial Peritonitis
Henry Ford St. John Hospital
22101 Moross Rd, 
Detroit, MI 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Nitin Jain is a Radiologist in Detroit, Michigan. Dr. Jain is rated as an Experienced provider by MediFind in the treatment of Spontaneous Bacterial Peritonitis. His top areas of expertise are Acute Lymphoblastic Leukemia (ALL), Small Lymphocytic Lymphoma (SLL), Ascites, Bone Marrow Aspiration, and Endoscopy.

His clinical research consists of co-authoring 492 peer reviewed articles and participating in 13 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Radiology
Licenses
Diagnostic Radiology in MI
Hospital Affiliations
Henry Ford Health Warren Hospital
Henry Ford Health St John Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Health Alliance Plan
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID

Locations

Henry Ford St. John Hospital
22101 Moross Rd, Detroit, MI 48236
Other Locations
Henry Ford Warren Hospital
11800 E 12 Mile Rd, Warren, MI 48093

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

13 Clinical Trials

Atezolizumab (PD-L1 mAb) in Combination With Obinutuzumab and Venetoclax for Patients With Chronic Lymphocytic Leukemia and Richter Transformation
Atezolizumab (PD-L1 mAb) in Combination With Obinutuzumab and Venetoclax for Patients With Chronic Lymphocytic Leukemia and Richter Transformation
Enrollment Status: Recruiting
Publish Date: August 14, 2025
Intervention Type: Biological, Other, Drug
Study Drugs: Atezolizumab, Obinutuzumab, Venetoclax
Study Phase: Phase 2
A Phase I/II Study to Evaluate the Safety and Anti-Tumor Activity of ADCT-602 Targeting CD22 in Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia
A Phase I/II Study to Evaluate the Safety and Anti-Tumor Activity of ADCT-602 Targeting CD22 in Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia
Enrollment Status: Terminated
Publish Date: December 12, 2025
Intervention Type: Biological
Study Drug: ADCT-602 Monoclonal Antibody
Study Phase: Phase 1/Phase 2
First-Line Therapy With Ibrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (GA-101) (iFCG) for Patients With Chronic Lymphocytic Leukemia (CLL) With Mutated IGHV Gene and Non-Del(17p)
First-Line Therapy With Ibrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (GA-101) (iFCG) for Patients With Chronic Lymphocytic Leukemia (CLL) With Mutated IGHV Gene and Non-Del(17p)
Enrollment Status: Active_not_recruiting
Publish Date: September 05, 2025
Intervention Type: Drug, Biological
Study Drugs: Cyclophosphamide, Fludarabine, Ibrutinib, Obinutuzumab
Study Phase: Phase 2
A Phase II Study of Venetoclax and Ibrutinib in Patients With Chronic Lymphocytic Leukemia (CLL)
A Phase II Study of Venetoclax and Ibrutinib in Patients With Chronic Lymphocytic Leukemia (CLL)
Enrollment Status: Active_not_recruiting
Publish Date: August 15, 2025
Intervention Type: Drug, Other
Study Drugs: Ibrutinib, Venetoclax
Study Phase: Phase 2
Peripheral Nerve Stimulation(PNS) for Subacromial Impingement Syndrome(SIS)
Peripheral Nerve Stimulation(PNS) for Subacromial Impingement Syndrome(SIS)
Enrollment Status: Completed
Publish Date: June 17, 2025
Intervention Type: Other, Device
Study Phase: Not Applicable
A Phase I-II Study of the Combination of Ruxolitinib or Dasatinib With Chemotherapy in Patients With Philadelphia Chromosome (Ph)-Like Acute Lymphoblastic Leukemia (ALL)
A Phase I-II Study of the Combination of Ruxolitinib or Dasatinib With Chemotherapy in Patients With Philadelphia Chromosome (Ph)-Like Acute Lymphoblastic Leukemia (ALL)
Enrollment Status: Terminated
Publish Date: June 08, 2025
Intervention Type: Drug, Biological, Other
Study Phase: Phase 2
A Phase I/II Dose-Escalation and Expansion Study of the Selective PKC-β Inhibitor MS-553 in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
A Phase I/II Dose-Escalation and Expansion Study of the Selective PKC-β Inhibitor MS-553 in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Enrollment Status: Terminated
Publish Date: April 10, 2025
Intervention Type: Drug
Study Drug: MS-553
Study Phase: Phase 1/Phase 2
Ipilimumab Combined With Ibrutinib and Nivolumab for Patients With Chronic Lymphocytic Leukemia (CLL) and Richter Transformation (RT)
Ipilimumab Combined With Ibrutinib and Nivolumab for Patients With Chronic Lymphocytic Leukemia (CLL) and Richter Transformation (RT)
Enrollment Status: Withdrawn
Publish Date: February 28, 2025
Intervention Type: Drug, Biological
Study Drugs: Ibrutinib, Ipilimumab, Nivolumab
Study Phase: Phase 1
Nivolumab Combined With Ibrutinib for Relapsed, Refractory or High-Risk Untreated Patients With Chronic Lymphocytic Leukemia (CLL)
Nivolumab Combined With Ibrutinib for Relapsed, Refractory or High-Risk Untreated Patients With Chronic Lymphocytic Leukemia (CLL)
Enrollment Status: Completed
Publish Date: March 20, 2024
Intervention Type: Drug, Biological, Other
Study Drugs: Ibrutinib, Nivolumab
Study Phase: Phase 2
A Phase IIa Study of BL-8040 in Combination With Nelarabine for Relapsed or Refractory T-Acute Lymphoblastic Leukemia/ Lymphoblastic Lymphoma
A Phase IIa Study of BL-8040 in Combination With Nelarabine for Relapsed or Refractory T-Acute Lymphoblastic Leukemia/ Lymphoblastic Lymphoma
Enrollment Status: Terminated
Publish Date: October 31, 2023
Intervention Type: Drug
Study Drugs: BL-8040 CD34-Positive Hematopoietic Cells, Nelarabine
Study Phase: Phase 2
A Phase I/II Study of Bosutinib in Combination With Inotuzumab Ozogamicin in CD22-Positive Philadelphia-Chromosome Positive Acute Lymphoblastic Leukemia and Chronic Myeloid Leukemia Lymphoid Blast Phase
A Phase I/II Study of Bosutinib in Combination With Inotuzumab Ozogamicin in CD22-Positive Philadelphia-Chromosome Positive Acute Lymphoblastic Leukemia and Chronic Myeloid Leukemia Lymphoid Blast Phase
Enrollment Status: Completed
Publish Date: July 17, 2023
Intervention Type: Biological, Drug
Study Drugs: Bosutinib, Inotuzumab, Ozogamicin
Study Phase: Phase 1/Phase 2
A Phase 1, Open-label, Adaptive Dose-escalation, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Anti-tumor Activity of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)
A Phase 1, Open-label, Adaptive Dose-escalation, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Anti-tumor Activity of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)
Enrollment Status: Terminated
Publish Date: May 24, 2021
Intervention Type: Drug
Study Phase: Phase 1
A Phase 1, Open-label, Dose-escalation, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Activity of ADCT 301 in Patients With Relapsed or Refractory CD25-positive Acute Myeloid Leukemia (AML) or CD25-positive Acute Lymphoblastic Leukemia
A Phase 1, Open-label, Dose-escalation, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Activity of ADCT 301 in Patients With Relapsed or Refractory CD25-positive Acute Myeloid Leukemia (AML) or CD25-positive Acute Lymphoblastic Leukemia
Enrollment Status: Terminated
Publish Date: February 26, 2020
Intervention Type: Drug
Study Phase: Phase 1
View 12 Less Clinical Trials

492 Total Publications

Correction: Long term results of venetoclax combined with FLAG-IDA induction and consolidation for newly diagnosed and relapsed or refractory acute myeloid leukemia.
Correction: Long term results of venetoclax combined with FLAG-IDA induction and consolidation for newly diagnosed and relapsed or refractory acute myeloid leukemia.
Journal: Leukemia
Published: December 10, 2025
Similar Doctors
Experienced in Spontaneous Bacterial Peritonitis
Dr. Alexander Tassopoulos
Radiology
Experienced in Spontaneous Bacterial Peritonitis
Dr. Alexander Tassopoulos
Radiology

Henry Ford Hospital

2799 W Grand Blvd, 
Detroit, MI 
 (10.4 miles away)
313-916-7425
Languages Spoken:
English
See accepted insurances

Alexander Tassopoulos is a Radiologist in Detroit, Michigan. Dr. Tassopoulos is rated as an Experienced provider by MediFind in the treatment of Spontaneous Bacterial Peritonitis. His top areas of expertise are Spontaneous Bacterial Peritonitis, Ascites, Secondary Peritonitis, Peritonitis, and Splenectomy.

Experienced in Spontaneous Bacterial Peritonitis
Dr. Hakmin Park
Radiology
Experienced in Spontaneous Bacterial Peritonitis
Dr. Hakmin Park
Radiology

Henry Ford Hospital

2799 W Grand Blvd, 
Detroit, MI 
 (10.4 miles away)
313-916-2600
Languages Spoken:
English
See accepted insurances

Hakmin Park is a Radiologist in Detroit, Michigan. Dr. Park is rated as an Advanced provider by MediFind in the treatment of Spontaneous Bacterial Peritonitis. His top areas of expertise are Visceromegaly, Ascites, Alagille Syndrome, and Fibrolamellar Carcinoma.

Experienced in Spontaneous Bacterial Peritonitis
Dr. Mishal Mendiratta
Radiology
Experienced in Spontaneous Bacterial Peritonitis
Dr. Mishal Mendiratta
Radiology

University Of Michigan Medical Center

1500 E Medical Center Dr, 
Ann Arbor, MI 
 (40.0 miles away)
734-936-4000
Languages Spoken:
English
See accepted insurances

Mishal Mendiratta is a Radiologist in Ann Arbor, Michigan. Dr. Mendiratta is rated as a Distinguished provider by MediFind in the treatment of Spontaneous Bacterial Peritonitis. Her top areas of expertise are Liver Cancer, Fibrolamellar Carcinoma, Visceromegaly, Cholangiocarcinoma (Bile Duct Cancer), and Hepato-Pancreato-Biliary Surgery.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Jain's expertise for a condition
ConditionClose
View All 8 Advanced Conditions
View All 48 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile